Returns
NAV and returns as at 20 Aug 2026
Lumpsum · point to point
1W
-0.39%
1M
+0.38%
3M
+6.43%
6M
+14.44%
YTD
+14.44%
1Y
+10.28%
2Y CAGR
—
3Y CAGR
—
5Y CAGR
—
10Y CAGR
—
SIP · XIRR on monthly instalments
6M SIP
+39.1%
1Y SIP
+21.86%
2Y SIP
—
3Y SIP
—
5Y SIP
—
10Y SIP
—
Full history SIP
+19.68%
Periods up to one year are absolute; longer periods are annualised (CAGR). SIP figures are the XIRR of a fixed monthly instalment over the same window. — means this scheme’s NAV history does not cover that period — across all 1648 schemes, 68% have a 3-year figure, 48.8% a 5-year one, and 32.7% a 10-year one.
Top holdings
as at 31 Jul 2026 · source: AMC monthly portfolio disclosure
Sun Pharmaceutical Industries LimitedPharmaceuticals & Biotechnology
8.82%
Torrent Pharmaceuticals LimitedPharmaceuticals & Biotechnology
8.58%
Divi's Laboratories LimitedPharmaceuticals & Biotechnology
6.66%
Lupin LimitedPharmaceuticals & Biotechnology
6.46%
IPCA Laboratories LimitedPharmaceuticals & Biotechnology
5.72%
Apollo Hospitals Enterprise LimitedHealthcare Services
5.35%
Laurus Labs LimitedPharmaceuticals & Biotechnology
5.24%
Fortis Healthcare LimitedHealthcare Services
4.55%
AstraZeneca Pharma India LimitedPharmaceuticals & Biotechnology
4.05%
Glenmark Pharmaceuticals LimitedPharmaceuticals & Biotechnology
3.44%
Top 10 58.87%Securities 30Securities total 96.61%Cash & equivalents 3.39%
The ten largest securities by weight, out of 30 disclosed. Weight is percent of net assets as filed. Cash-equivalent lines (TREPS, reverse repo, net receivables, margin) and derivative legs are counted in the chips above but not ranked among securities, because a short futures leg is filed as a negative weight and sorting it alongside a shareholding describes no portfolio. A portfolio is a point-in-time filing and changes every month.
Risk
Volatility · annualised · 1Y 2M
12.47%
Max drawdown · 1Y 2M
-11.11%
Volatility is the annualised standard deviation of daily NAV moves over the 1Y 2M of NAV history this scheme has, 01 Jul 2025 to 20 Aug 2026; max drawdown is the deepest peak-to-trough fall in that same window. Where a scheme has less than three years of NAV, the window is what it actually has and is labelled as such — never as three years. Sharpe is as disclosed in the scheme key-ratio feed (as at 24 July 2026).
Beta and alpha are not shown. No benchmark series in the source.
Cost
Expense ratio1.04%
Category average1.73%
Exit load1%
52W high / low₹11.013 / ₹9.0594
Expense ratio 1.04% vs a category average of 1.73% — 0.69 percentage points lower. Among Sectoral/ Thematic schemes disclosing an expense ratio it is 60th of 166, cheapest first.
Expense ratio and category average are as disclosed against this scheme in the source; 78.5% of schemes here carry one. The ratio is charged inside the NAV, so every return on this page is already net of it.
Scheme facts
SEBI sub-category
Sectoral/ Thematic
Plan / option
Direct Growth
Benchmark
BSE Health Care - TRI
Fund manager
Sanjay Chawla, Ankeet Pandya
Launched
09 Jun 2025
NAV history here
1.1y
ISIN
INF251K01VA5
AMFI scheme code
153604
SEBI riskometer
Very High
Exit load
1%
Lock-in
None
Minimum lumpsum
₹1,000
Exit load, as disclosed: NIL upto 10% of units and 1% for remaining units on or before 1Y · Nil after 1Y
Not shown on this page, and why
Star rating — GFS is an AMFI-registered distributor (ARN-169480), not a SEBI-registered investment adviser. It does not rate schemes.
Scheme AUM — Scheme-level AUM is not in the source; only AMC-total AUM, which is a different number.
Minimum SIP — Not present in the source.
Beta and alpha — No benchmark series in the source.